Actualités Oaktree Acquisition Corp II - OACB | Actions New York Stock Exchange

Notification Filed by a National Securities Exchange to Report the Removal From Listing and Registration of Matured , Redeemed or Retired Securities (25)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 25 ...

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

Filed by Alvotech (Commission...

Alvotech und Oaktree Acquisition Corp. II melden Zustimmung der Aktionäre zum Unternehmenszusammenschluss

Zusammenschluss soll voraussichtlich am bzw. um den 15. Juni 2022 abgeschlossen werden Stammaktien von Alvotech sollen ab 16. Juni 2022 am...

Alvotech et Oaktree Acquisition Corp. II annoncent l'approbation des actionnaires pour le regroupement d'entreprises

Le regroupement d'entreprises devrait être finalisé (vers) le 15 juin 2022 Les actions ordinaires d'Alvotech devraient être négociées sous le...

Alvotech and Oaktree Acquisition Corp. II Announce Shareholder Approval of Business Combination

Business Combination anticipated to close on or about June 15, 2022 Ordinary shares of Alvotech expected to trade under the new ticker symbol...

Current Report Filing (8-k)

Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-fourth of one redeemable warrant false 0001820931 0001820931...

Oaktree Acquisition Corp. II Announces Delisting of its Securities Effective and Conditional Upon Consummation of its Pending Business Combination with Alvotech

Business Combination remains subject to satisfaction of customary closing conditions, including shareholder approval Oaktree Acquisition Corp...

Current Report Filing (8-k)

false 0001820931 0001820931 2022-05-31 2022-05-31 0001820931 oacb:UnitsEachConsistingOfOneClassAOrdinaryShare0.0001ParValueAndOneFourthOfOneRedee...

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

Filed by Alvotech (Commission File No. 333-261773) Pursuant to...

Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT04 and Reference Product Stelara®

The confirmatory clinical, safety and efficacy study for AVT04, biosimilar candidate to Stelara® (ustekinumab) met its primary endpoint AVT04...

Alvotech, Global Biotech Company, and Oaktree Acquisition Corp. II Announce June 7, 2022 Extraordinary General Meeting to Approve Business Combination

Alvotech Holdings S.A. (“Alvotech S.A.”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Oaktree Acquisition Corp II (OACB)

Votre Hub pour des idées et discussions en direct en temps réel

OACB Actualités

Notification Filed by a National Securities Exchange to Report the Removal From Listing and Registration of Matured , Redeemed or Retired Securities (25)

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

Alvotech und Oaktree Acquisition Corp. II melden Zustimmung der Aktionäre zum Unternehmenszusammenschluss

Alvotech et Oaktree Acquisition Corp. II annoncent l'approbation des actionnaires pour le regroupement d'entreprises

Alvotech and Oaktree Acquisition Corp. II Announce Shareholder Approval of Business Combination

Current Report Filing (8-k)

Oaktree Acquisition Corp. II Announces Delisting of its Securities Effective and Conditional Upon Consummation of its Pending Business Combination with Alvotech

Current Report Filing (8-k)

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT04 and Reference Product Stelara®

Current Report Filing (8-k)

Quarterly Report (10-q)

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

Alvotech Announces Positive Results from a Pharmacokinetic Similarity Study for AVT04, a Proposed Biosimilar to Stelara®

Alvotech, Global Biotech Company, and Oaktree Acquisition Corp. II Announce June 7, 2022 Extraordinary General Meeting to Approve Business Combination

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Oaktree Acquisition Corp II (OACB) Actualités

Oaktree Acquisition Corp II (OACB)

Votre Hub pour des idées et discussions en direct en temps réel

OACB Actualités

Notification Filed by a National Securities Exchange to Report the Removal From Listing and Registration of Matured , Redeemed or Retired Securities (25)

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

Alvotech und Oaktree Acquisition Corp. II melden Zustimmung der Aktionäre zum Unternehmenszusammenschluss

Alvotech et Oaktree Acquisition Corp. II annoncent l'approbation des actionnaires pour le regroupement d'entreprises

Alvotech and Oaktree Acquisition Corp. II Announce Shareholder Approval of Business Combination

Current Report Filing (8-k)

Oaktree Acquisition Corp. II Announces Delisting of its Securities Effective and Conditional Upon Consummation of its Pending Business Combination with Alvotech

Current Report Filing (8-k)

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT04 and Reference Product Stelara®

Current Report Filing (8-k)

Quarterly Report (10-q)

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

Alvotech Announces Positive Results from a Pharmacokinetic Similarity Study for AVT04, a Proposed Biosimilar to Stelara®

Alvotech, Global Biotech Company, and Oaktree Acquisition Corp. II Announce June 7, 2022 Extraordinary General Meeting to Approve Business Combination

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités